These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19358945)

  • 1. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure.
    Chen HH; Cataliotti A; Schirger JA; Martin FL; Harstad LK; Burnett JC
    J Am Coll Cardiol; 2009 Apr; 53(15):1302-8. PubMed ID: 19358945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
    Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
    J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
    Chen HH; Cataliotti A; Schirger JA; Martin FL; Burnett JC
    Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1093-7. PubMed ID: 15627648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
    Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
    Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
    Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
    J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous administration of brain natriuretic peptide in experimental heart failure.
    Chen HH; Grantham JA; Schirger JA; Jougasaki M; Redfield MM; Burnett JC
    J Am Coll Cardiol; 2000 Nov; 36(5):1706-12. PubMed ID: 11079680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity.
    Boerrigter G; Costello-Boerrigter LC; Harty GJ; Huntley BK; Cataliotti A; Lapp H; Burnett JC
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1744-50. PubMed ID: 19386989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.
    Chen Y; Harty GJ; Huntley BK; Iyer SR; Heublein DM; Harders GE; Meems L; Pan S; Sangaralingham SJ; Ichiki T; Burnett JC
    Am J Physiol Regul Integr Comp Physiol; 2018 Mar; 314(3):R407-R414. PubMed ID: 29187381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation.
    Boerrigter G; Costello-Boerrigter LC; Harty GJ; Lapp H; Burnett JC
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R897-901. PubMed ID: 17068158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Horton DP; Burnett JC
    J Card Fail; 2004 Apr; 10(2):115-9. PubMed ID: 15101022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention.
    La Villa G; Riccardi D; Lazzeri C; Casini Raggi V; Dello Sbarba A; Tosti Guerra C; Fronzaroli C; Foschi M; Laffi G; Gentilini P
    Hepatology; 1995 Dec; 22(6):1745-50. PubMed ID: 7489983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure.
    Chen HH; Schirger JA; Cataliotti A; Burnett JC
    Eur J Heart Fail; 2006 Nov; 8(7):681-6. PubMed ID: 16459135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective endothelin B receptor blockade does not influence BNP-induced natriuresis in man.
    van der Zander K; Houben AJ; Webb DJ; Udo E; Kietselaer B; Hofstra L; De Mey JG; de Leeuw PW
    Kidney Int; 2006 Mar; 69(5):864-8. PubMed ID: 16518347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.
    Grantham JA; Borgeson DD; Burnett JC
    Am J Physiol; 1997 Apr; 272(4 Pt 2):R1077-83. PubMed ID: 9140004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction.
    Clavell AL; Stingo AJ; Aarhus LL; Burnett JC
    Am J Physiol; 1993 Dec; 265(6 Pt 2):R1416-22. PubMed ID: 8285286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure).
    Wan SH; McKie PM; Schirger JA; Slusser JP; Hodge DO; Redfield MM; Burnett JC; Chen HH
    JACC Heart Fail; 2016 Jul; 4(7):539-547. PubMed ID: 26874387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension.
    Lazzeri C; Franchi F; Porciani C; Fronzaroli C; Casini Raggi V; De Feo ML; Mannelli M; Cersosimo RM; La Villa G
    Am J Hypertens; 1995 Aug; 8(8):799-807. PubMed ID: 7576396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.